Literature DB >> 6234856

Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.

D E Kuhl, E J Metter, W H Riege, C H Markham.   

Abstract

Patterns of local cerebral glucose utilization were measured with positron emission tomography using the fluorine-18-labeled fluorodeoxyglucose (18FDG) method in 8 patients with Parkinson's disease, in 13 patients with Huntington's disease, in 15 subjects at risk for Huntington's disease, and in aged-matched normal control subjects. On the average, global cerebral metabolism in patients with Parkinson's disease was moderately reduced (20%), but the relative distribution of glucose utilization throughout the brain in these patients was normal. These results support the conclusion that alterations of the nigrostriatal pathway in Parkinson's disease have no major selective effect on the metabolism of particular cerebral regions. In Huntington's disease, however, there was a characteristic decrease in glucose utilization in the caudate nuclei and putamen, and this local hypometabolism appeared early and preceded bulk tissue loss. In patients with Huntington's disease, glucose utilization typically was normal throughout the rest of the brain, regardless of the severity of symptoms and despite the apparent shrinkage of brain tissue. The results also suggest the possibility that the caudate nuclei may be hypometabolic in some asymptomatic subjects who are potential carriers of the autosomal dominant gene for Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234856     DOI: 10.1002/ana.410150723

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

Review 1.  Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease.

Authors:  L Besret; A L Kendall; S B Dunnett
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

Review 2.  PET: its clinical role in neurology.

Authors:  D Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

3.  Factor analysis of regional cerebral glucose metabolic rates in healthy men.

Authors:  Z Szabo; E E Camargo; S Sostre; I Shafique; B Sadzot; J M Links; R F Dannals; H N Wagner
Journal:  Eur J Nucl Med       Date:  1992

4.  Long latency EMG responses in early diagnosis of Huntington's chorea.

Authors:  F Leblhuber; E Windhager; F Reisecker; H Rittmannsberger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

5.  Abnormalities in the tricarboxylic Acid cycle in Huntington disease and in a Huntington disease mouse model.

Authors:  Nima N Naseri; Hui Xu; Joseph Bonica; Jean Paul G Vonsattel; Etty P Cortes; Larry C Park; Jamshid Arjomand; Gary E Gibson
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

6.  Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers.

Authors:  V Hahn-Barma; B Deweer; A Dürr; C Dodé; J Feingold; B Pillon; Y Agid; A Brice; B Dubois
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

Review 7.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

Review 8.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

9.  Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.

Authors:  Nicole M Lewandowski; Yvette Bordelon; Adam M Brickman; Sergio Angulo; Usman Khan; Jordan Muraskin; Erica Y Griffith; Paula Wasserman; Liliana Menalled; Jean Paul Vonsattel; Karen Marder; Scott A Small; Herman Moreno
Journal:  Neurobiol Dis       Date:  2012-12-04       Impact factor: 5.996

Review 10.  Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

Authors:  Rodrigo A Quintanilla; Gail V W Johnson
Journal:  Brain Res Bull       Date:  2009-07-19       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.